Patents Assigned to Randox Laboratories Ltd.
-
Patent number: 10209167Abstract: The present invention provides a novel method of in vitro sample preparation for the analysis of proteins. In a first aspect, the present invention is a method comprising the separation and individual treatment of blood platelets and platelet-poor plasma obtained from a platelet-rich plasma sample. This allows for optimal treatment of both fractions and overcomes many of the problems associated with current methods. In a second aspect of the present invention the platelet sample preparation method can be implemented before a biochip based immunoassay for the detection of platelet proteins in combination with plasma proteins.Type: GrantFiled: November 13, 2014Date of Patent: February 19, 2019Assignee: RANDOX LABORATORIES LTD.Inventors: Michael Veitinger, Maria Zellner
-
Patent number: 10168331Abstract: The present invention provides a method and a solid state device for identifying the presence of urothelial cancer in a patient comprising assigning the subject to a sub-population according to smoking habits, measuring the level of each biomarker of a panel of biomarkers in one or more samples obtained from the subject; and correlating the measured levels of the panel of biomarkers with the likelihood of the subject having urothelial cancer such that the subject can be classified as having urothelial cancer or as being a control.Type: GrantFiled: April 2, 2015Date of Patent: January 1, 2019Assignee: RANDOX LABORATORIES LTD.Inventors: Mark Ruddock, Cherith Reid, John Lamont, Stephen Fitzgerald, Ricardo De Matos Simoes, Kathleen Williamson
-
Patent number: 9927429Abstract: The present invention provides an in vitro method to aid the diagnosis of Alzheimer's disease (AD) or Mild Cognitive Impairment (MCI), comprising determining the level of expression of one or more tropomyosin isoform(s) corresponding to P09493-3 and/or P09493-1 in a patient's sample. A kit comprising probes that bind to tropomyosin isoforms P09493-3 and P09493-1 is also provided.Type: GrantFiled: July 8, 2013Date of Patent: March 27, 2018Assignee: RANDOX LABORATORIES LTD.Inventors: Maria Zellner, Ellen Umlauf
-
Patent number: 9892229Abstract: The invention provides a method of defining the likelihood of a subject having bladder cancer, comprising the steps of: (A) assessing the subject's likelihood of having bladder cancer by: i. identifying at least one sub-population group appropriate to the subject; ii. determining the level of one or more biomarkers selected according to the sub-population group in a sample obtained from the subject; iii. inputting each of the biomarker values into an algorithm to produce an output value; and iv. correlating the output value with the likelihood of the subject having bladder cancer, wherein the sub-population group is selected according to smoking habits, gender, presence/absence of stone disease, history of benign prostate enlargement (BPE) or prescription of anti-hypertensive, anti-platelet and/or anti-ulcer medication, and (B) determining the subject's stratified risk level of serious disease by: v.Type: GrantFiled: October 16, 2013Date of Patent: February 13, 2018Assignee: RANDOX LABORATORIES LTD.Inventors: Mark William Ruddock, Cherith N. Reid, Kate E. Williamson, Frank Emmert-Streib, John V. Lamont, Peter Fitzgerald
-
Patent number: 9880178Abstract: The present invention provides an ex vivo method for aiding the diagnosis of Alzheimer's disease in a patient comprising: (i) determining the number of alleles of ApoE4 in the patient's genome; (ii) determining the combined expression level of at least three platelet proteins in a platelet sample from the patient; and (iii) comparing the resulting value of step (ii) to a control value, wherein the at least three platelet proteins include at least one isoform of alpha-tropomyosin containing exon 1a and at least two platelet proteins selected from monoamine oxidase-B, coagulation factor XIIIa, wild-type GSTO-1 or mutant GSTO-1, wherein a result higher than the control value is indicative of Alzheimer's disease.Type: GrantFiled: October 3, 2013Date of Patent: January 30, 2018Assignee: RANDOX LABORATORIES LTD.Inventors: Ellen Umlauf, Maria Zellner
-
Patent number: 9766109Abstract: A capacitive liquid level sensor is provided comprising a capacitive probe having a capacitance and comprising a sensing tip wherein the capacitive probe is configured such that the capacitance of the probe changes when the sensing tip is exposed to liquid. A signal generator operates to supply an electrical signal alternating between a high and low state to the capacitive probe, the electrical signal being configured such that the probe is alternately charged and discharged when the signal is high or low respectively. A comparator operates to detect the magnitude of an electrical signal across the capacitive probe and provides a first output signal value when the detected signal magnitude is greater than a predetermined threshold value and a second output signal value when the signal magnitude is less than the threshold value.Type: GrantFiled: August 5, 2011Date of Patent: September 19, 2017Assignee: RANDOX LABORATORIES LTD.Inventors: Ian Armstrong, Michael Duffy, Stephen Peter Fitzgerald
-
Patent number: 9726678Abstract: The invention relates to methods of diagnosing Alzheimer's disease (AD) in a subject and methods of determining the prognosis in patients with AD. The adhesion molecules P-selectin and L-selectin are described for the first time for use as biomarkers to aid in the diagnosis of AD. The invention further describes the use of one or more of L-selectin, MCP-1, IL-1?, IL-8 and IFN-? to aid in the prognosis of either accelerated cognitive decline (ACD) or slow cognitive decline (SCD) in patients with AD.Type: GrantFiled: April 15, 2010Date of Patent: August 8, 2017Assignee: RANDOX LABORATORIES LTD.Inventors: Massimiliano Corsi, Stephen Peter Fitzgerald, John V. Lamont, Paul Innocenzi
-
Patent number: 9707561Abstract: There is provided an assay fluid delivery system comprising an array of fluid reservoirs (62), each of which is selectively actuatable to deliver a respective fluid to a fluid channel structure; and a fluid delivery control system (50) comprising a plurality of reciprocally mounted actuators, each associated with a respective reservoir and being movable between a retracted position and an actuating position at which it causes fluid to be delivered from the corresponding reservoir, a plurality of cams (22) with different profiles mounted on a common, rotatable cam shaft (6), each cam being engaged with a respective one of the actuators whereby rotation of the cams causes movement of the corresponding actuators between the retracted and actuating positions, and a motor coupled to the cam shaft for rotating the cam shaft, wherein the cams are shaped relative to one another so as to cause the corresponding actuators to actuate the reservoirs in a predetermined sequence and for predetermined respective times.Type: GrantFiled: November 19, 2014Date of Patent: July 18, 2017Assignee: Randox Laboratories Ltd.Inventors: Jonathan Matear, Robson Pang, Stuart Jackson, David Sloan
-
Publication number: 20170184611Abstract: The present invention provides biomarker-based methods for diagnosing stroke in a patient suspected of having suffered a stroke, and also for discriminating between ischemic stroke and transient ischemic attack. Substrates comprising probes for specific combinations of biomarkers useful in the methods of the invention are also described.Type: ApplicationFiled: March 13, 2017Publication date: June 29, 2017Applicant: Randox Laboratories Ltd.Inventors: John Lamont, Ivan Mc Connell, Peter Fitzgerald
-
Publication number: 20170095819Abstract: A biochip well is disclosed, including a vessel containing a well therewithin, the vessel forming at least base and side walls of the well and defining at least one aperture giving access to the well, and further including retaining means for holding a biochip at a predetermined position within the well, the well including a laterally offset region into which the biochip does not protrude when held at the predetermined position by the retaining means. Also disclosed are sealed well assemblies and apparatus and methods for opening sealed wells.Type: ApplicationFiled: November 23, 2016Publication date: April 6, 2017Applicant: RANDOX LABORATORIES, LTD.Inventors: Gareth WILSON, Michael HOOKS, Peter FITZGERALD, John LAMONT, Ivan MCCONNELL
-
Patent number: 9540129Abstract: A biochip well is disclosed, including a vessel containing a well therewithin, the vessel forming at least base and side walls of the well and defining at least one aperture giving access to the well, and further including retaining means for holding a biochip at a predetermined position within the well, the well including a laterally offset region into which the biochip does not protrude when held at the predetermined position by the retaining means. Also disclosed are sealed well assemblies and apparatus and methods for opening sealed wells.Type: GrantFiled: July 26, 2011Date of Patent: January 10, 2017Assignee: RANDOX LABORATORIES LTD.Inventors: Gareth Wilson, Michael Hooks, Peter Fitzgerald, John Lamont, Ivan McConnell
-
Patent number: 9447469Abstract: The present disclosure provides a method for identifying whether a subject is more or less likely to be responsive to VEGF-based therapy, comprising screening a nucleic acid sample obtained from the subject to provide output information which identifies the presence or absence of an allelic variant, wherein the presence or absence of an allelic variant indicates whether the subject is more or less likely to be responsive to VEGF-based therapy.Type: GrantFiled: July 3, 2014Date of Patent: September 20, 2016Assignee: RANDOX LABORATORIES LTD.Inventor: John V. Lamont
-
Patent number: 9382568Abstract: The present invention provides an in vitro method for determining the resistance or sensitivity of a cell line or patient sample to a deoxyribonucleoside kinase-dependent drug, wherein the method comprises the steps of: (i) treating a patient sample or cell line, or a portion thereof, with a deoxyribonucleoside kinase-dependent drug; (ii) lysing the cells of the patient sample or cell line from step (i); (iii) optionally, mixing a portion of the cell lysate from step (ii) with a bioluminescent reporter bacteria incorporating a gene coding for deoxyribonucleoside kinase; (iv) mixing a portion of the cell lysate from (ii) with a bioluminescent reporter bacteria incorporating a gene coding for a deoxyribonucleoside kinase and a deoxyribonucleoside kinase transcription promoter; (v) mixing a portion of the cell lysate from step (ii) with a bioluminescent reporter bacteria incorporating a gene coding for a deoxyribonucleoside kinase, a deoxyribonucleoside kinase transcription promoter and a dephosphorylating agentType: GrantFiled: August 10, 2009Date of Patent: July 5, 2016Assignees: RANDOX LABORATORIES LTD., UNIVERSITY OF THE WEST OF ENGLANDInventors: Vyvyan Clare Salisbury, Habib Mahmoud Alloush, Margaret Ann Smith, Paul John Innocenzi, Mark William Ruddock, Ashley Diane Martin
-
Patent number: 9302831Abstract: A valve for a reagent bottle is provided, the valve including a resilient membrane configured to extend across an opening in the reagent bottle, the resilient membrane having at least one slit extending therethrough. Also disclosed is a dispensing apparatus for dispensing a reagent from a reagent bottle, the dispensing apparatus comprising: a probe assembly having a probe adapted for insertion into the reagent bottle through the valve and an extraction mechanism for drawing reagent out of the reagent bottle through the probe. A valve opening assembly is provided, which is adapted to open the valve of the reagent bottle such that the probe can pass through the valve without contacting the valve.Type: GrantFiled: July 26, 2011Date of Patent: April 5, 2016Assignee: Randox Laboratories Ltd.Inventors: Gareth Wilson, Carl Wrigglesworth, Peter Fitzgerald, John Lamont, Ivan McConnell
-
Patent number: 9222949Abstract: The present invention provides an immunoassay method for detecting or determining the amount of salvinorin A, salvinorin B and/or analogues thereof in an in vitro sample, an antibody for salvinorin A, salvinorin B and/or analogues thereof and a kit for detecting the presence of or determining the amount of salvinorin A, salvinorin B and its analogues thereof in a sample.Type: GrantFiled: April 27, 2010Date of Patent: December 29, 2015Assignee: RANDOX LABORATORIES, LTD.Inventors: Stephen P. Fitzgerald, Robert I. McConnell, Philip A. Lowry, Elouard Benchikh
-
Publication number: 20150126385Abstract: The present invention provides biomarker-based methods for diagnosing stroke in a patient suspected of having suffered a stroke, and also for discriminating between ischemic stroke and transient ischemic attack. Substrates comprising probes for specific combinations of biomarkers useful in the methods of the invention are also described.Type: ApplicationFiled: December 3, 2012Publication date: May 7, 2015Applicant: RANDOX LABORATORIES LTD.Inventors: John Lamont, Ivan Mc Connell, Peter Fitzgerald
-
Publication number: 20140336283Abstract: The invention describes epistatic interactions between single nucleotide polymorphisms on genes associated with blood pressure and provides an application for their use in a method to determine an individual's susceptibility to hypertension and hence whether anti-hypertensive treatment will be beneficial for said individual. In addition gene expression levels are also linked to blood pressure and may also be used to determine susceptibility to hypertension.Type: ApplicationFiled: December 21, 2012Publication date: November 13, 2014Applicant: RANDOX LABORATORIES LTD.Inventors: Sophie Visvikis-Siest, Said El Shamieh, Helena Murray, John Lamont, Peter Fitzgerald
-
Patent number: 8852953Abstract: The invention relates to novel immunogens, antibodies, methods and kits for use in immunoassays to detect and quantify zaleplon, metabolites of zaleplon and indiplon. These are the first described immunoassays for these compounds and have greater sensitivity than alternative analytical techniques.Type: GrantFiled: July 16, 2010Date of Patent: October 7, 2014Assignee: Randox Laboratories Ltd.Inventors: Elouard Benchikh, Stephen Peter Fitzgerald, Philip Andrew Lowry, Ivan Robert McConnell
-
Publication number: 20140072987Abstract: The disclosure relates to methods of detecting bladder cancer including assaying a patient sample for the levels of certain combinations of biomarkers. The disclosure also relates to methods for determining the efficacy of a drug for the treatment of bladder cancer.Type: ApplicationFiled: September 12, 2013Publication date: March 13, 2014Applicant: RANDOX LABORATORIES LTD.Inventors: Mark W. Ruddock, Cherith N. Reid, Kathleen Williamson, John V. Lamont, Stephen P. Fitzgerald
-
Patent number: D815752Type: GrantFiled: November 28, 2014Date of Patent: April 17, 2018Assignee: Randox Laboratories Ltd.Inventors: Stuart Jackson, Ivan McConnell, John Lamont, Peter Fitzgerald